Display options
Cite
Ehrmann S, Helms J, Joret A, et al. Nephrotoxic drug burden among 1001 critically ill patients: impact on acute kidney injury. Ann Intensive Care. 2019;9(1):106doi: 10.1186/s13613-019-0580-1.
Ehrmann, S., Helms, J., Joret, A., Martin-Lefevre, L., Quenot, J. P., Herbrecht, J. E., Benzekri-Lefevre, D., Robert, R., Desachy, A., Bellec, F., Plantefeve, G., Bretagnol, A., Dargent, A., Lacherade, J. C., Meziani, F., Giraudeau, B., Tavernier, E., Dequin, P. F. (2019). Nephrotoxic drug burden among 1001 critically ill patients: impact on acute kidney injury. Annals of intensive care, 9(1), 106. https://doi.org/10.1186/s13613-019-0580-1
Ehrmann, Stephan, et al. "Nephrotoxic drug burden among 1001 critically ill patients: impact on acute kidney injury." Annals of intensive care vol. 9,1 (2019): 106. doi: https://doi.org/10.1186/s13613-019-0580-1
Ehrmann S, Helms J, Joret A, Martin-Lefevre L, Quenot JP, Herbrecht JE, Benzekri-Lefevre D, Robert R, Desachy A, Bellec F, Plantefeve G, Bretagnol A, Dargent A, Lacherade JC, Meziani F, Giraudeau B, Tavernier E, Dequin PF. Nephrotoxic drug burden among 1001 critically ill patients: impact on acute kidney injury. Ann Intensive Care. 2019 Sep 23;9(1):106. doi: 10.1186/s13613-019-0580-1. PMID: 31549274; PMCID: PMC6757082.
Copy Download .nbib Format: NLM
Share it on

Ann Intensive Care. 2019 Sep 23;9(1):106. doi: 10.1186/s13613-019-0580-1.

Nephrotoxic drug burden among 1001 critically ill patients: impact on acute kidney injury.

Annals of intensive care

Stephan Ehrmann, Julie Helms, Aurélie Joret, Laurent Martin-Lefevre, Jean-Pierre Quenot, Jean-Etienne Herbrecht, Dalila Benzekri-Lefevre, René Robert, Arnaud Desachy, Fréderic Bellec, Gaëtan Plantefeve, Anne Bretagnol, Auguste Dargent, Jean-Claude Lacherade, Ferhat Meziani, Bruno Giraudeau, Elsa Tavernier, Pierre-François Dequin,

Affiliations

  1. INSERM CIC 1415, CHRU de Tours, Médecine intensive réanimation, 2, Bd Tonnellé, 37044, Tours Cedex 9, France. [email protected].
  2. Université de Tours, faculté de médecine, Tours, France. [email protected].
  3. ImmunoRhumatologie Moléculaire, INSERM UMR_S1109, LabEx TRANSPLANTEX, FHU OMICARE, FMTS, Université de Strasbourg, Strasbourg, France.
  4. Médecine Intensive Réanimation, Nouvel Hôpital Civil, Hôpitaux universitaires de Strasbourg, Strasbourg, France.
  5. INSERM CIC 1415, CHRU de Tours, Médecine intensive réanimation, 2, Bd Tonnellé, 37044, Tours Cedex 9, France.
  6. Réanimation polyvalente, CHD de Vendée, La Roche-sur-Yon, France.
  7. Department of Intensive Care, François Mitterrand University Hospital, Dijon, France.
  8. Lipness Team, INSERM Research Center LNC-UMR1231 and LabExLipSTIC, University of Burgundy, Dijon, France.
  9. INSERM CIC 1432, Clinical Epidemiology, University of Burgundy, Dijon, France.
  10. Réanimation médicale, Hôpitaux universitaires de Strasbourg, Hôpital Hautepierre, Strasbourg, France.
  11. Médecine intensive réanimation, CHR d'Orléans, Orléans, France.
  12. Réanimation médicale, CHU de Poitiers, Poitiers, France.
  13. Réanimation polyvalente, CH d'Angoulême, Angoulême, France.
  14. Réanimation, CH de Montauban, Montauban, France.
  15. Réanimation polyvalente, CH Victor Dupouy, Argenteuil, France.
  16. INSERM UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Université de Strasbourg, Strasbourg, France.
  17. Inserm CIC 1415, CHRU de Tours, Tours, France.
  18. Université de Tours, faculté de médecine, Tours, France.

PMID: 31549274 PMCID: PMC6757082 DOI: 10.1186/s13613-019-0580-1

Abstract

BACKGROUND: Nephrotoxic drug prescription may contribute to acute kidney injury (AKI) occurrence and worsening among critically ill patients and thus to associated morbidity and mortality. The objectives of this study were to describe nephrotoxic drug prescription in a large intensive-care unit cohort and, through a case-control study nested in the prospective cohort, to evaluate the link of nephrotoxic prescription burden with AKI.

RESULTS: Six hundred and seventeen patients (62%) received at least one nephrotoxic drug, among which 303 (30%) received two or more. AKI was observed in 609 patients (61%). A total of 351 patients were considered as cases developing or worsening AKI a given index day during the first week in the intensive-care unit. Three hundred and twenty-seven pairs of cases and controls (patients not developing or worsening AKI during the first week in the intensive-care unit, alive the case index day) matched on age, chronic kidney disease, and simplified acute physiology score 2 were analyzed. The nephrotoxic burden prior to the index day was measured in drug.days: each drug and each day of therapy increasing the burden by 1 drug.day. This represents a semi-quantitative evaluation of drug exposure, potentially easy to implement by clinicians. Nephrotoxic burden was significantly higher among cases than controls: odds ratio 1.20 and 95% confidence interval 1.04-1.38. Sensitivity analysis showed that this association between nephrotoxic drug prescription in the intensive-care unit and AKI was predominant among the patients with lower severity of disease (simplified acute physiology score 2 below 48).

CONCLUSIONS: The frequently observed prescription of nephrotoxic drugs to critically ill patients may be evaluated semi-quantitatively through computing drug.day nephrotoxic burden, an index significantly associated with subsequent AKI occurrence, and worsening among patients with lower severity of disease.

Keywords: Acute [MeSH]; Aminoglycosides [MeSH]; Contrast media [MeSH]; Diuretics [MeSH]; Intensive-care units [MeSH]; Kidney tubular necrosis; Renal insufficiency [MeSH]; Vancomycin [MeSH]

References

  1. JAMA. 2005 Aug 17;294(7):813-8 - PubMed
  2. Antimicrob Agents Chemother. 2016 Apr 22;60(5):3248 - PubMed
  3. Antimicrob Agents Chemother. 2014 Dec;58(12):7468-74 - PubMed
  4. Curr Opin Crit Care. 2016 Dec;22(6):542-545 - PubMed
  5. Medicine (Baltimore). 2017 Feb;96(7):e6023 - PubMed
  6. Intensive Care Med. 2017 Jun;43(6):785-794 - PubMed
  7. Kidney Int. 2012 Jun;81(12):1172-8 - PubMed
  8. Proc R Soc Med. 1965 May;58:295-300 - PubMed
  9. Intensive Care Med. 2017 Jun;43(6):829-840 - PubMed
  10. J Crit Care. 2013 Oct;28(5):687-94 - PubMed
  11. Crit Care Med. 2018 Jan;46(1):12-20 - PubMed
  12. J Am Soc Nephrol. 2004 Jun;15(6):1597-605 - PubMed
  13. Kidney Int. 2004 Oct;66(4):1613-21 - PubMed
  14. Intensive Care Med. 2015 Aug;41(8):1411-23 - PubMed
  15. J Clin Invest. 2014 Jun;124(6):2355-63 - PubMed
  16. N Engl J Med. 2014 Jul 3;371(1):58-66 - PubMed
  17. Br J Clin Pharmacol. 1985 Feb;19(2):191-201 - PubMed
  18. Expert Opin Drug Saf. 2008 Nov;7(6):679-90 - PubMed
  19. Ren Fail. 2011;33(8):758-64 - PubMed
  20. Intensive Care Med. 2009 Oct;35(10):1692-702 - PubMed
  21. Crit Care Med. 2014 Apr;42(4):878-85 - PubMed
  22. Crit Care Med. 2017 Jul;45(7):e745-e746 - PubMed
  23. Crit Care. 2011;15(3):R135 - PubMed
  24. Curr Opin Crit Care. 2005 Dec;11(6):555-65 - PubMed
  25. Crit Care Med. 2010 Jun;38(6 Suppl):S169-74 - PubMed
  26. Stat Sci. 2010 Feb 1;25(1):1-21 - PubMed
  27. Intensive Care Med. 2017 Jun;43(6):730-749 - PubMed
  28. Nephrol Dial Transplant. 2003 Jan;18(1):212-4 - PubMed
  29. Paediatr Drugs. 2017 Feb;19(1):59-67 - PubMed
  30. Crit Care Med. 2008 Apr;36(4 Suppl):S198-203 - PubMed
  31. Shock. 2010 Aug;34(2):109-16 - PubMed
  32. Cochrane Database Syst Rev. 2014 Jan 07;(1):CD003344 - PubMed
  33. Crit Care Med. 2017 Jan;45(1):69-74 - PubMed
  34. JAMA. 1993 Dec 22-29;270(24):2957-63 - PubMed
  35. Br J Clin Pharmacol. 2017 Jun;83(6):1341-1349 - PubMed
  36. Kidney Int. 2005 Jul;68(1):14-22 - PubMed
  37. Antimicrob Agents Chemother. 2009 Jul;53(7):2887-91 - PubMed

Publication Types